Oxurion NV Logo

Oxurion NV

Acquires European pharmaceutical subcontractors to build an integrated healthcare services group.

OXUR | BR

Overview

Corporate Details

ISIN(s):
BE0974487192
LEI:
549300VWY8KVDFKLDM59
Country:
Belgium
Address:
Gaston Geenslaan 1, 3001 Heverlee
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Oxurion is a company specializing in acquiring majority stakes in promising European pharmaceutical subcontractors. Its ambition is to build an integrated group of subcontractors to serve healthcare stakeholders. The company holds a 72% stake in Axiodis CRO, a contract research organization specialized in biometrics. This strategy represents a shift from its historical focus as a biopharmaceutical company developing therapies for retinal diseases like Geographic Atrophy (GA) and Age-related Macular Degeneration (AMD).

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-02 18:00
Major Shareholding Notification
OXUR-Transparency-Notification-EN-20251002.pdf
English 352.2 KB
2025-10-02 18:00
Major Shareholding Notification
OXUR-Transparency-Notification-NL-20251002.pdf
Dutch 378.2 KB
2025-09-30 18:00
Interim Report
OXUR GLOBAL - Financial report 30-06-2025 (EN) FINAL.pdf
English 412.9 KB
2025-09-30 18:00
Interim Report
OXUR GLOBAL - Financial report 30-06-2025 (NL) FINAL.pdf
Dutch 420.8 KB
2025-09-30 18:00
Report Publication Announcement
OXUR_Publish-H1-2025-results_EN.pdf
English 211.4 KB
2025-09-30 18:00
Report Publication Announcement
OXUR_Publication-H1-2025-resultats_FR.pdf
French 161.8 KB
2025-09-30 18:00
Report Publication Announcement
OXUR_Publicatie-H1-2025-resultaten_NL.pdf
Dutch 211.0 KB
2025-09-08 18:00
Major Shareholding Notification
OXUR-Transparency-Notification-EN-20250903.pdf
English 371.9 KB
2025-09-08 18:00
Major Shareholding Notification
OXUR-Transparency-Notification-NL-20250903.pdf
Dutch 396.3 KB
2025-09-01 18:00
Capital/Financing Update
OXUR-Contrat-atlas-crypto-EN-20250901.pdf
English 190.2 KB
2025-09-01 18:00
Capital/Financing Update
OXUR-Contrat-atlas-crypto-FR-20250901.pdf
French 125.2 KB
2025-09-01 18:00
Capital/Financing Update
OXUR-Contrat-atlas-crypto-NL-20250901-1.pdf
Dutch 214.2 KB
2025-09-01 18:00
Major Shareholding Notification
OXUR-Transparency-Notification-EN-20250901.pdf
English 1.2 MB
2025-09-01 18:00
Major Shareholding Notification
OXUR-Transparency-Notification-NL-20250901.pdf
English 1.3 MB
2025-08-07 18:00
Legal Proceedings Report
OXUR-New-Development-Strategy-EN-20250806.pdf
English 195.7 KB

Automate Your Workflow. Get a real-time feed of all Oxurion NV filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Oxurion NV via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2022-03-07 Bareldam SA Close relation Buy 1,180,555 1,700,000.00 EUR
2021-09-30 Lavinia D. Clay 2009 Revocable Trust Close relation Other 2,766,337 5,601,002.52 EUR

Peer Companies

Company Country Ticker View
PC İLETİŞİM VE MEDYA HİZMETLERİ SANAYİ TİCARET A.Ş. Logo
Integrated media group providing data-driven advertising and media solutions for global brands.
Türkiye PCILT
Peers Co.,Ltd. Logo
Accelerating tech adoption with consulting, HR services, and proprietary IT/AI solutions.
Japan 7066
PeptiDream Inc. Logo
Discovers peptide therapeutics via a proprietary platform and markets radiopharmaceuticals.
Japan 4587
PharmaLundensis AB Logo
Develops treatments for heavy metal toxicity and serious respiratory illnesses.
Sweden PHAL
Pharos iBio Co., Ltd. Logo
AI-powered drug development for rare and refractory diseases, focusing on oncology.
South Korea 388870
PhoenixBio Co.,Ltd. Logo
CRO providing humanized liver mouse models and testing services for preclinical drug development.
Japan 6190
P&K Skin Research Center Co.,Ltd. Logo
Clinical research for dermatological testing in cosmetics, pharma, and health food sectors.
South Korea 347740
Plantarc Bio Ltd. Logo
Developing high-yield, resilient crops via gene discovery for global seed companies.
Israel PLNT
Polymetal International plc Logo
A top global gold and silver producer with mining and exploration operations in Kazakhstan.
Kazakhstan POLY
Poxel Logo
Develops drugs for metabolic diseases, including NASH, rare diseases, and an approved diabetes drug.
France POXEL

Talk to a Data Expert

Have a question? We'll get back to you promptly.